Quick Answer
RELMADA THERAPEUTICS, INC. reported Net Income Loss of -$57.39 million for the year ending 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +28.3% in Net Income Loss from 2024 to 2025.
- This data is from RELMADA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2012 to 2025), RELMADA THERAPEUTICS, INC.'s Net Income Loss has declined by 476,046.4%.
- Historical annual values: Fiscal year 2025: -$57.39 million | Fiscal year 2024: -$79.98 million | Fiscal year 2023: -$98.79 million | Fiscal year 2022: -$157.04 million | Fiscal year 2021: -$125.75 million | Fiscal year 2020: -$59.46 million | Fiscal year 2019: -$15.01 million | Fiscal year 2019: -$17.32 million | Fiscal year 2018: -$8.96 million | Fiscal year 2017: -$6.29 million | Fiscal year 2016: -$2.97 million | Fiscal year 2015: -$20.80 million | Fiscal year 2013: -$19.87 million | Fiscal year 2013: -$45.0 thousand | Fiscal year 2012: -$12.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: